Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction
Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction
Objective: Erectile dysfunction (ED) is a common condition in patients with heart failure (HF), which impairs quality of life. Our
study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin
receptor-neprilysin inhibitor (ARNI) treatment in addition to the current treatment, in terms of ED at the end of 6 months.
Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart
failure. The patients’ demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring
questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those
who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared.
Results: The median age of the patients was 53 (years). The median ejection fraction (EF) value was calculated to be 30% and no
significant difference was found between the groups (p: 0.122). It was found that N-terminal pro-brain natriuretic peptide (NT-pro-
BNP) levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those
who had not (respectively, 245 pg/ml, 200 pg/ml; p: 0.003). In the analysis performed to detect the presence of ED, it was discovered
that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment (p: 0.031) compared to
that in the group that had not (p: 0.031). When the ED sub-parameters were compared in terms of the 6-month change rate, it was
found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was
found in the other parameters (p: 0.001, p: 0.029).
Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of
life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for
6 months than in patients who had not.
___
- Rosamond W, Flegal K, Furie K, et al. Heart disease and
stroke statistics 2008 update: a report from the American
Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation 2008;29:117:25-146. doi: 10.1161/
CIRCULATIONAHA.107.187998
- Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
doi: 10.1056/NEJM200.006.153422407.
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ,
McKinlay JB. Impotence and its medical and psychosocial
correlates: Results of the Massachusetts Male Aging Study. J
Urol 1994; 151:54-61. doi: 10.1016/s0022-5347(17)34871-1
- Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M,
Engelmann U. Epidemiology of erectile dysfunction: Results
of the “Cologne Male Survey.” Int J Impot Res 2000; 12:305-
11. doi: 10.1038/sj.ijir.3900622
- Schouten BWV, Bosch JLHR, Bernsen RMD, Blanker MH,
Thomas S, Bohnen AM. Incidence rates of erectile dysfunction
in the Dutch general population. Effects of definition, clinical
relevance, and duration of follow-up in the Krimpen Study. Int
J Impot Res 2005; 17:58-62. doi: 10.1038/sj.ijir.3901264
- Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction,
and cardiac risk (the Second Princeton Consensus
Conference). Am J Cardiol 2005;96:313-21. doi: 10.1016/j.
amjcard.2005.12.018
- Rastogi S, Rodriguez J, Kapur V, Schwarz ER. Why do patients
with heart failure suffer from erectile dysfunction? A critical
review and suggestions on how to approach this problem. Int J
Impot Res 2005;17 Suppl 1:25-36. doi: 10.1038/sj.ijir.3901426
- Bocchi E A, Guimarães G, Mocelin A, Bacal F, Bellotti G,
Ramires J F. Sildenafil effects on exercise, neurohormonal
activation, and erectile dysfunction in congestive heart
failure: a double-blind, placebo-controlled, randomized
study followed by a prospective treatment for erectile
dysfunction. Circulation 2002;106:1097-103. doi: 10.1161/01.
cir.000.002.7149. 83473.b6
- Schwarz ER, Kapur V, Bionat S, Rastogi S, Gupta R, Rosanio
S. The prevalence and clinical relevance of sexual dysfunction
in women and men with chronic heart failure. Int J Impot Res
2008;20:85-91. doi: 10.1038/sj.ijir.3901613
- Costa C, Virag R. The endothelial–erectile dysfunction
connection: An essential update. J Sex Med 2009; 6 2390-404.
doi: 10.1111/j.1743-6109.2009.01356.x
- Hodges LD, Kirby M, Solanki J, O’Donnell J, Brodie DA.
The temporal relationship between erectile dysfunction and
cardiovascular disease. Int J Clin Pract 2007;61:2019-25.
doi:10.1111/j.1742-1241.2007. 01629.x
- Anne I, Thorson MD. Sexual activity and the cardiac patient.
Am J Geriatr Cardiol 2003;12 : 38-40. doi: 10.1111/j.1076-
7460.2003.01755.x.
- Karavitakis M, Komninos C, Theodorakis PN, et al. Evaluation
of sexual function in hypertensive men receiving treatment:
a review of current guidelines recommendation. J Sex Med
2011;8:2405-14. doi: 10.1111/j.1743-6109.2011.02342. x.
- Gottlieb S, Khatta M, Friedmann E, et al. The influence of
age, gender, and race on the prevalence of depression in
heart failure patients. J Am Coll Cardiol 2004;43:1542-9. doi
:10.1016/j.jacc.2003.10.064
- Rosen, R.C., Riley, A., Wagner, G., Osterloh, I., Kirkpatrick,
J., Mishra, A. (1997). The International Index of Erectile
Function (IIEF): a multidimensional scale for assessment of
erectile dysfunction. Urology 1997;49:822-30. doi: 10.1016/
s0090-4295(97)00238-0
- Ceyhun G, Erbay G. The relationship between ProNT BNP
levels and erectiledysfunction in patients with chronic
congestive heart failure. Ann Med Res 2021; 28: 652-6.
doi:10.5455/annalsmedres.2020.06.676
- McMurray JJ, Packer M, Desai AS, et al . Angiotensinneprilysin
inhibition versus enalapril in heart failure. N Engl J
Med 2014;371:993-1004. doi: 10.1056/NEJMoa1409077
- Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby
DE. Neutral endopeptidase inhibition augments vascular
actions of bradykinin in patients treated with angiotensinconverting
enzyme inhibition. Hypertension 2004;44:913-8.
doi: 10.1161/01.HYP.000.014.6483.78994.56.
- Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum
H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the
human forearm vascular bed: effect of neutral endopeptidase
inhibition and comparison with proadrenomedullin NH2-
terminal 20 peptide (PAMP). Br J Clin Pharmacol 2001;
52:159-64. doi: 10.1046/j.0306-5251.2001.1420. x.
- Marci C, Zheng W, Walther T. Interactions between
angiotensin ll and atrial natriuretic peptide in renomedullary
interstitial cells: the role of neutral endopeptidase. Nephron
Physiol 2006; 103:149-56. doi: 10.1159/000092457
- Kuhn M. Molecular physiology of natriuretic peptide
signalling. Basic Res Cardiol 2004; 99:76-82. doi: 10.1007/
s00395.004.0460-0.
- Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the
angiotensin-receptor neprilysin inhibitor on cardiac reverse
remodeling: Meta-analysis. J Am Heart Assoc 2019;8:012272.
doi: 10.1161/JAHA.119.012272.
- Canale ML, Coviello K, Solarino G, et al. Case Series:
Recovery of chemotherapy-related acute heart failure by
the combined use of sacubitril valsartan and wearable
cardioverter defibrillator: A novel winning combination in
cardio-oncology. Front Cardiovasc Med 2022; 9:801143. doi:
10.3389/fcvm.2022.801143.
- Trivedi RK, Polhemus DJ, Li Z, et al. Combined angiotensin
receptor-neprilysin inhibitors improve cardiac and vascular
function via increased NO bioavailability in heart failure. J Am
Heart Assoc 2018;7:008268. doi:10.1161/JAHA.117.008268
- Claudino M.A., Mora A, Janussi S, et al. Effect of Entresto
(valsartan+sacubitril) in the cardiac function and contractile
response of detrusor and corpus cavernosum smooth muscles
of heart failure rats. FASEB Journal 2020; 34:1-1 doi:10.1096/
fasebj.2020.34.s1.07018
- Zhuang C, Guo Z, Wang W, Sun R, Qi M, Yu J. Sacubitril/
valsartan improves sexual function and fibrosis of the clitoral
and vaginal tissues in female spontaneously hypertensive
rats. J Cardiovasc Pharmacol 2022;79:858-72. doi: 10.1097/
FJC.000.000.0000001251.
- The PARADOR (Comparing ARNI With ACE Inhibitor on
Endothelial Function) trial is a planned multisite, randomized,
double-blind trial designed to compare the effects of sacubitril/
valsartan with enalapril on endothelial function in patients
with HFrEF ClinicalTrials.gov Identifier: NCT03917459
Novartis. Comparing ARNI with ACE inhibitor on endothelial
function (PARADOR), https://clinicaltrials.gov/ct2/show/
NCT03119623. NLM identifier: NCT03119623 (accessed
December 2017 – completed August 2019)